Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $526000.0.

  • ARS Pharmaceuticals' Current Deferred Revenue changed N/A to $526000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $526000.0, marking a year-over-year change of. This contributed to the annual value of $557000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Current Deferred Revenue stood at $526000.0.
  • ARS Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $3.1 million during Q4 2022, with a 5-year trough of $10000.0 in Q1 2023.
  • Its 5-year average for Current Deferred Revenue is $996142.9, with a median of $557000.0 in 2024.
  • The largest annual percentage gain for ARS Pharmaceuticals' Current Deferred Revenue in the last 5 years was 11530.54% (2022), contrasted with its biggest fall of 11530.54% (2022).
  • Over the past 5 years, ARS Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $1.5 million in 2021, then surged by 115.31% to $3.1 million in 2022, then tumbled by 99.68% to $10000.0 in 2023, then surged by 5470.0% to $557000.0 in 2024, then fell by 5.57% to $526000.0 in 2025.
  • Its Current Deferred Revenue stands at $526000.0 for Q3 2025, versus $746000.0 for Q2 2025 and $540000.0 for Q1 2025.